Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

被引：13
|
作者：
Rimassa, Lorenza
Cicin, Irfan
Blanc, Jean-Frederic
Klumpen, Heinz Josef
Zagonel, Vittorina
Tran, Albert
Kim, Stefano Chong Hun
Lin, Zhong-Zhe
Tam, Vincent C.
Hazra, Saswati
Mangeshkar, Milan
El-Khoueiry, Anthony
Cheng, Ann-Lii
Meyer, Tim
Kelley, Robin Kate
Abou-Alfa, Ghassan K.
机构：
[1] Humanitas Clin & Res Ctr, Rozzano, Italy
[2] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey
[3] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Oncol, Amsterdam, Netherlands
[5] Ist Oncol Veneto, IRCCS, Padua, Italy
[6] Grp Hosp Archet, Nice, France
[7] Univ Besancon, Ctr Hosp, Besancon, France
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[10] Exelixis Inc, San Francisco, CA USA
[11] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[12] Natl Taiwan Univ Hosp, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4090
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
    El-Khoueiry, A.
    Meyer, T.
    Cheng, A.
    Rimassa, L.
    Sen, S.
    Milwee, S.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S220 - S220
  • [33] Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
    Freemantle, Nick
    Mollon, Patrick
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Kelley, Robin K.
    Baron, Ari D.
    Benzaghou, Fawzi
    Mangeshkar, Milan
    Abou-Alfa, Ghassan K.
    EUROPEAN JOURNAL OF CANCER, 2022, 168 : 91 - 98
  • [34] Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth
    Gruellich, Carsten
    Nott, Louise M.
    Cuff, Katharine
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard
    Pal, Sumanta
    Powles, Thomas
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 1 - 10
  • [35] Extended linifanib therapy in patients (pts) with advanced hepatocellular carcinoma (HCC) in a phase II trial
    Chen, P. J.
    Yong, W.
    Carr, B. I.
    Sato, T.
    Qin, Q.
    Qian, J.
    Ansell, P. J.
    McKeegan, E. M.
    McKee, M. D.
    Ricker, J. L.
    Carlson, D. M.
    Toh, H. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Grullich, Carsten
    Nott, Louise M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [37] Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma
    Vogel, A.
    Merle, P.
    Granito, A.
    Ikeda, M.
    LeBerre, M. -A
    Ozgurdal, K.
    Bruix, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 223 - 223
  • [38] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik-Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han Chong
    Gorbunova, Vera
    Eskens, Ferry
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [39] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
    Spencer, Kristen Renee
    Ramsingh, Giridharan
    Mohamed, Nehal
    Pal, Sumanta K.
    Rimassa, Lorenza
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345